Physician profile
Wright D Shields
NPI 1720034937
$3,507.73
in general payments reported to CMS, 2019-2025
56 companies · $16.19 in 2025
The $16.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $620 · 2021: $867 · 2022: $656 · 2023: $378 · 2025: $16.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $580.96 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $288.38 | 2019-2023 | Prolastin-C Liquid |
| Abbvie INC. | $262.79 | 2019-2023 | Vraylar, Rinvoq, Humira |
| Actelion Pharmaceuticals US, INC. | $215.05 | 2019-2023 | Opsumit |
| Amgen INC. | $187.74 | 2019-2020 | |
| Genentech USA, INC. | $169.81 | 2021-2023 | Xolair, Actemra, Esbriet |
| Janssen Biotech, INC. | $153.92 | 2019-2023 | Tremfya |
| Pfizer INC. | $153.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $89.12 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $80.59 | 2020-2023 | Ultomiris |
| Lundbeck LLC | $80.50 | 2020-2021 | |
| Daiichi Sankyo INC. | $76.11 | 2019-2022 | |
| Novo Nordisk INC | $69.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.68 | 2019-2021 |
Show all 55 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wright Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.